Tiakis Biotech
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2025-09-01attributed |
| Founded | unknown |
| Headquarters | Kiel, Germany |
| Industry | health |
| Stage | unknown |
| Website | tiakis.bio |
Tiakis Biotech develops therapies that boost the body's own protective mechanisms in pulmonary arterial hypertension and post-surgical inflammation. It targets PAH patients and people undergoing highly invasive surgery at risk of inflammatory complications. Partnerships with Stanford and Edinburgh anchor a preventive, mechanism-driven approach rather than symptom management.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-09-01 | grant | $2.7M | undisclosed |
Detected tech stack
Apache HTTP Server, apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | tiakis.bio, read 2026-05-08 |
| Description | self-reported | tiakis.bio, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.